Prognostic Significance of Early Declines in Pulmonary Function After Allogeneic Hematopoietic Stem Cell Transplantation

被引:0
|
作者
Yadav, Hemang [1 ]
Torghabeh, Mehrdad Hefazi [2 ]
Hogan, William J. [2 ]
Limper, Andrew H. [1 ]
机构
[1] Mayo Clin, Dept Pulm & Crit Care Med, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Hematol, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
Bone marrow transplantation; pulmonary function; spirometry; diffusing capacity; bronchiolitis obliterans; RESPIRATORY-DISTRESS-SYNDROME; COMORBIDITY INDEX; RISK-ASSESSMENT; STANDARDIZATION; COMPLICATIONS; VALIDATION; SPIROMETRY; SOCIETY; MODEL;
D O I
10.4187/respcare.10925
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Pulmonary function test (PFT) impairments are common after allogeneic hematopoietic stem cell transplantation. The prognostic significance of these declines on outcomes is not well understood. The objectives were to determine the frequency of declines in pulmonary function (FVC, FEV1, and diffusing capacity for carbon monoxide [DLCO]) in the early posttransplantation period; and to determine the prognostic significance of these declines on mortality or development of bronchiolitis obliterans syndrome. METHODS: This was a retrospective cohort study conducted at Mayo Clinic, Rochester, Minnesota. PFTs were obtained at baseline and at day +100. Competing risk survival models were developed, which accounted for pretransplantation pulmonary function and relapse status. RESULTS: Between January 1, 2005, and December 31, 2020, 1,145 subjects underwent allogeneic hematopoietic stem cell transplantation and had a pre-transplantation PFT performed. Of these, 900 (78.6%) survived to day 100 and had post-transplantation PFTs performed (median [interquartile range] 97 [94-103] d). A decline of >= 10% in FEV1, FVC, or DLCO was seen in 401 of 900 subjects (44.5%). Declines of >= 20% in FEV1 (hazard ratio 1.65, 95% CI 1.07-2.56; P = .02), FVC (hazard ratio 1.72, 95% CI [1.11-2.67]; P = .02), and D-LCO (hazard ratio 1.46, 95% CI 1.04-2.07; P = .028) were all associated with reduced survival when compared with those with < 10% decline in PFT measures. These findings were independent of pre-transplantation pulmonary function or relapse status. Bronchiolitis obliterans syndrome was diagnosed in 118 subjects (10.3%), and there was no relationship between early PFT decline and a subsequent diagnosis of bronchiolitis obliterans syndrome. The subjects who received myeloablative conditioning with cyclophosphamide plus total body irradiation or cyclophosphamide plus fludarabine plus total body irradiation were more likely to have lower spirometry values after hematopoietic stem cell transplantation. The subjects who received reduced intensity conditioning or nonmyeloablative conditioning with fludarabine plus total body irradiation were more likely to have higher post-hematopoietic stem cell transplantation FEV1, FVC, and DLCO. CONCLUSIONS: An absolute decline of >= 20% in FEV1, FVC, or D-LCO were associated with reduced survival independent of pre-transplantation pulmonary function or relapse status. In contrast to previous work, early declines in PFT measures were not associated with future development of bronchiolitis obliterans syndrome.
引用
收藏
页码:1406 / 1416
页数:11
相关论文
共 50 条
  • [31] Erythrocytosis after allogeneic hematopoietic stem cell transplantation
    Hino, Yutaro
    Doki, Noriko
    Kurosawa, Shuhei
    Yamamoto, Keita
    Sakaguchi, Masahiro
    Harada, Kaito
    Ikegawa, Shuntaro
    Shingai, Naoki
    Hattori, Kenichiro
    Senoo, Yasushi
    Igarashi, Aiko
    Najima, Yuho
    Kobayashi, Takeshi
    Kakihana, Kazuhiko
    Sakamaki, Hisashi
    Ohashi, Kazuteru
    CLINICAL TRANSPLANTATION, 2017, 31 (04)
  • [32] Jaundice After Allogeneic Hematopoietic Stem Cell Transplantation
    Mendizabal, Manuel
    Chen, Terina
    Reddy, K. Rajender
    HEPATOLOGY, 2009, 50 (06) : 2044 - 2045
  • [33] Rhabdomyolysis After Allogeneic Hematopoietic Stem Cell Transplantation
    Q. Jiang
    B. H. Zhang
    Indian Journal of Hematology and Blood Transfusion, 2016, 32 : 504 - 506
  • [34] Malakoplakia After Allogeneic Hematopoietic Stem Cell Transplantation
    Robinson, Tracy
    Streu, Erin
    ONCOLOGY NURSING FORUM, 2015, 42 (05) : 558 - 561
  • [35] Rhabdomyolysis After Allogeneic Hematopoietic Stem Cell Transplantation
    Jiang, Q.
    Zhang, B. H.
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2016, 32 (04) : 504 - 506
  • [36] Plasticity after allogeneic hematopoietic stem cell transplantation
    Rovo, Alicia
    Gratwohl, Alois
    BIOLOGICAL CHEMISTRY, 2008, 389 (07) : 825 - 836
  • [37] Polyomaviruses After Allogeneic Hematopoietic Stem Cell Transplantation
    Mendoza, Maria Alejandra
    Imlay, Hannah
    VIRUSES-BASEL, 2025, 17 (03):
  • [38] Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation
    Blaser, Bradley W.
    Kim, Haesook
    Plutzky, Jorge
    Alyea, Edwin, III
    Ho, Vincent
    Cutler, Corey
    Armand, Philippe
    Koreth, John
    Antin, Joseph H.
    Soiffer, Robert
    BLOOD, 2010, 116 (21) : 1419 - 1419
  • [39] Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation
    Choi, Yunsuk
    Choi, Eun-Ji
    Lee, Jung-Hee
    Lee, Kyoo-Hyung
    Jo, Jae-Cheol
    Park, Han-Seung
    Lee, Yoo Jin
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Lee, Je-Hwan
    CLINICAL TRANSPLANTATION, 2021, 35 (03)
  • [40] Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation
    Bondeelle, Louise
    Bergeron, Anne
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (01) : 105 - 119